2022
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases
Chia D, Sundar R, Kim G, Ang J, Lum J, Nga M, Goh G, Seet J, Chee C, Tan H, Ho J, Ngoi N, Lee M, Muthu V, Chan G, Pang A, Ang Y, Choo J, Lim J, Teh J, Lwin A, Soon Y, Shabbir A, So J, Yong W. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases. Annals Of Surgical Oncology 2022, 29: 8597-8605. PMID: 36070113, DOI: 10.1245/s10434-022-11998-z.Peer-Reviewed Original ResearchConceptsGastric cancer peritoneal metastasisIP-PTXConversion surgeryIntraperitoneal paclitaxelMedian OSSystemic chemotherapyPeritoneal metastasisSC groupConversion to negative cytologyResultsThe median OSProgression-free survivalPhase II studyMethodsForty-four patientsIntravenous oxaliplatinMedian PFSOral capecitabineSystemic capecitabineExtraperitoneal metastasesNegative cytologyPeritoneal diseaseOverall survivalPerformance statusPrimary endpointSecondary endpointsIP cohort
2021
Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases.
Chia D, Sundar R, Kim G, Ang J, Lum J, Nga M, Cheng Ean C, Tan H, Ho J, Ngoi N, Lee M, Muthu V, Chan G, Pang A, Ang Y, Choo J, Lim J, Shabbir A, Yong W, So J. Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases. Journal Of Clinical Oncology 2021, 39: 165-165. DOI: 10.1200/jco.2021.39.3_suppl.165.Peer-Reviewed Original ResearchIP paclitaxelSystemic chemotherapyPeritoneal metastasisConversion surgeryGastric cancerMedian OSSC groupProspective phase 2 trialIP groupProgression-free survivalPhase II studyBaseline performance statusWound-related complicationsStandard-of-careGCPM patientsIntraperitoneal paclitaxelIV oxaliplatinMedian PFSSystemic capecitabineExtraperitoneal metastasesNegative cytologyOverall survivalPerformance statusPrimary endpointSecondary endpoints
2018
Risk factors for conversion surgery to total hip arthroplasty of a hemiarthroplasty performed for a femoral neck fracture
Grosso M, Danoff J, Thacher R, Murtaugh T, Hickernell T, Shah R, Macaulay W. Risk factors for conversion surgery to total hip arthroplasty of a hemiarthroplasty performed for a femoral neck fracture. Hip International 2018, 28: 168-172. PMID: 29890908, DOI: 10.1177/1120700018768654.Peer-Reviewed Original ResearchConceptsFemoral neck fracturesLeg length discrepancyConversion surgeryAbsence of dementiaNeck fracturesRisk factorsIndex surgeryHip arthroplastyYounger ageHigher Body Mass IndexContralateral femoral headConversion of hemiarthroplastyBody mass indexMultivariate logistic regressionCase-control studyTotal hip arthroplastyRisk of conversionFemoral head sizeHead sizeControl patientsPatient characteristicsMass indexLength discrepancyUnivariate analysisIntraoperative considerations
2017
Risk factors for conversion surgery to total hip arthroplasty of a hemiarthroplasty performed for a femoral neck fracture.
Grosso M, Danoff J, Thacher R, Murtaugh T, Hickernell T, Shah R, Macaulay W. Risk factors for conversion surgery to total hip arthroplasty of a hemiarthroplasty performed for a femoral neck fracture. Hip International 2017, 0. PMID: 29048693, DOI: 10.5301/hipint.5000547.Peer-Reviewed Original ResearchFemoral neck fracturesLeg length discrepancyConversion surgeryAbsence of dementiaNeck fracturesRisk factorsIndex surgeryHip arthroplastyYounger ageHigher Body Mass IndexContralateral femoral headConversion of hemiarthroplastyBody mass indexMultivariate logistic regressionCase-control studyTotal hip arthroplastyRisk of conversionFemoral head sizeHead sizeControl patientsPatient characteristicsMass indexLength discrepancyUnivariate analysisIntraoperative considerations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply